How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundaci-n-fls-de-lucha-contra-el-sida-las-enfermedades-infecciosas-y-la-promoci.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia pipeline: 5 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 3 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Descovy	Descovy	marketed			Other
PI-based regimen	PI-based regimen	marketed
Mpox Vaccine	Mpox Vaccine	marketed	vaccine		Immunology
Unique	Unique	marketed			Other
Silimarine	Silimarine	marketed			Other
Benzathine Penicilllin G	Benzathine Penicilllin G	phase 3	Beta-lactam antibiotic (penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan	Infectious Disease
Treatment and prophylaxis	Treatment and prophylaxis	phase 3	NRTI (nucleoside reverse transcriptase inhibitor)	Reverse transcriptase	Infectious Disease
Protease Inhibitor/ritonavir	Protease Inhibitor/ritonavir	phase 3	Protease inhibitor combination	HIV protease	Infectious Disease

Therapeutic area mix

Infectious Disease · 3
Other · 3
Immunology · 1
Infectious Diseases · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aduro Biotech, Inc. · 1 shared drug class
Advancis Pharmaceutical Corporation · 1 shared drug class
Aeras · 1 shared drug class
Aga Khan University · 1 shared drug class
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
Alba Maria Ropero · 1 shared drug class
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia:

Cite this brief

Drug Landscape (2026). Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-fls-de-lucha-contra-el-sida-las-enfermedades-infecciosas-y-la-promoci. Accessed 2026-05-17.